Conatus Pharmaceuticals Inc (NASDAQ:CNAT)

5.42
Delayed Data
As of Jun 15
 +0.12 / +2.26%
Today’s Change
3.22
Today|||52-Week Range
7.95
+17.32%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$116.9M

Company Description

Conatus Pharmaceuticals, Inc. engages in the development and commercialization of medicines for the treatment of liver diseases. It focuses in development of emricasan, an active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease, which reduce the activities of human caspases. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, Steven J. Mento and Charles J. Cashion on July 13, 2005 and is headquartered in San Diego, CA.

Contact Information

Conatus Pharmaceuticals, Inc.
16745 West Bernardo Drive
San Diego California 92127-7619
P:(858) 376-2600
Investor Relations:
(858) 376-2637

Employees

Shareholders

Individual stakeholders26.47%
Other institutional17.08%
Mutual fund holders16.03%

Top Executives

Steven J. MentoPresident, Chief Executive Officer & Director
Keith W. MarshallChief Operating & Financial Officer, Executive VP
Alfred P. SpadaCSO, Executive VP-Research & Development
Daniel L. RipleySenior VP-Business Development & Programme
David T. HagertyExecutive Vice President-Clinical Development